Overview
A large observational analysis of U.S. health records suggests that long-term use of some drugs prescribed for irritable bowel syndrome (IBS) is associated with a small but statistically significant increase in the risk of earlier death. The study was published April 8 in Communications Medicine and examined nearly 20 years of data on about 670,000 adults, making it the largest real-world look at long-term safety of common IBS treatments to date.
Key findings
– Long-term use of two opioid-derived antidiarrheal drugs — loperamide and diphenoxylate — was associated with roughly double the risk of death compared with nonuse in this analysis.
– Long-term use of antidepressants commonly prescribed to treat IBS symptoms was associated with about a 35% higher risk of death.
– Other medication classes reviewed, including antispasmodics and agents for constipation, were not linked to increased all-cause mortality in this study.
– Investigators emphasized these are associations, not proven cause-and-effect. The observed links could reflect higher rates of adverse events (for example, cardiovascular events, falls, stroke) among medication users or other confounding factors not fully accounted for.
What experts say
– Researchers note a major gap in long-term safety data: many people are diagnosed with IBS at a young age and may take medications for years, whereas most clinical trials run under a year. Patients and clinicians should be aware of this limitation when weighing prolonged treatment.
– Clinicians stress the absolute risk for any individual is likely small, and for many patients the symptom relief provided by these drugs can outweigh potential risks given the substantial impact of IBS on quality of life.
– The study authors and outside experts recommend caution, additional research to clarify mechanisms, and individualized discussions between patients and their clinicians about risks and benefits.
Background on IBS
IBS affects an estimated 25–45 million people in the U.S. Symptoms vary widely and can include abdominal pain, bloating, and altered bowel habits (diarrhea, constipation, or mixed patterns). Because the condition is heterogeneous and often long-term, treatment typically combines medication with lifestyle and behavioral approaches.
Treatment options to consider
– Medications can reduce pain, control diarrhea, and ease constipation and remain important for many patients.
– Nonpharmacologic strategies that may reduce medication needs include: a low-FODMAP diet guided by a dietitian, appropriate fiber adjustments, limiting trigger foods, regular exercise, good sleep, stress management, cognitive behavioral therapy or gut-directed hypnotherapy, and pelvic floor physical therapy or biofeedback when relevant.
– Complementary therapies such as acupuncture have shown mixed results.
Practical advice for patients
– Don’t panic if you are taking IBS medications. Instead, review your treatment plan with your clinician, especially if you have other health risks.
– Discuss expected benefits, alternative therapies, planned duration of use, and monitoring strategies to reduce risk.
– Further research is needed to determine whether particular subgroups are at higher risk and to understand potential mechanisms behind the associations observed.
Bottom line
This large observational study raises important questions about long-term safety for some IBS medications—notably certain antidiarrheals and some antidepressants—but does not prove cause and effect. The absolute risk for any one person appears small. Treatment choices should balance symptom control and quality of life against potential long-term risks and be made in partnership with a healthcare provider.